The Cheap Entry Trap: How Indian Tissue Manufacturers Set Themselves Up to Fail Twice

There is a default belief in Indian manufacturing that goes largely unexamined: to enter a market, you price cheap. Low price first, quality later. Earn your shelf space, prove your product, build margin once you're established.

The logic is not entirely wrong. The problem is what it forces you to do next.

A tissue manufacturer who enters the market with cheap, low-margin products builds their entire operation around those margins — the volume they need to move, the overheads they can carry, and critically, the equipment they can justify buying. Thin margins from cheap products are what push manufacturers toward cheap machines. Not ignorance. Not carelessness. Simple arithmetic.

And this is where one decision compounds into two.

There is a difference between selling cheap and making cheap that most discussions of market entry strategy skip over. Selling cheap means pricing aggressively to win share, while building a product worth more than you're charging for it. Making cheap means cutting the product itself — thinner tissue, inconsistent fold, unreliable count — to hit the price point. The first is a strategy. The second is a trap that the market locks you into the moment your first customer forms an opinion of your brand.

First impressions in this business are stickier than most manufacturers account for. Some do successfully pivot to better products and higher prices. But the buyers they built at cheap prices rarely follow them there. The brand memory is already set.

So the manufacturer is left running thin margins on a product they cannot easily upgrade — and shopping for machines on the same logic they used to price their napkins.

This is where the compounding begins in earnest.

A tissue operation running on thin margins cannot absorb downtime. One unplanned production stoppage does not just cost a repair bill — it costs the profit that day was supposed to generate. Both hits land simultaneously on a business with no buffer to absorb either. The manufacturers most exposed to this are the ones who bought cheap machines precisely because their margins left them no room for anything else.

The machine that looked like the responsible purchase — the one that protected the margin — becomes the thing that destroys it. Repeatedly.

The manufacturers who avoided this trap did not necessarily have more capital at the start. They made a different decision about what kind of business they were building. They entered with a product they could stand behind at a price that reflected it, to a buyer segment willing to pay for consistency. And they bought machines capable of delivering that consistency — not because they were optimistic, but because they understood that a machine running 300+ days a year for 20 years is not a cost to minimise. It is the asset that generates everything.

The cheap entry strategy is not wrong in every context. In tissue manufacturing, it has a specific failure mode: it ties every subsequent decision to the same logic that made the first one, until the whole structure is built on a foundation that was never meant to hold it.

The Tissue Industry Review is an independent editorial publication covering the tissue conversion and paper products manufacturing sector in India and globally.

Share this article